M&A / Deals Regeneron signs $2.32bn deal with Parabilis for Helicon conjugates Pharmaceutical TechnologyRegeneron Pharmaceuticals has signed a $2.32bn deal with Parabilis Medicines to develop therapeutic candidates, with a focus on AHCs.Read full story pharminent May 19, 2026 (Last updated: May 21, 2026) Pharmaceutical Technology Regeneron Pharmaceuticals has signed a $2.32bn deal with Parabilis Medicines to develop therapeutic candidates, with a focus on AHCs. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: SCOTUS won’t hear pharma’s IRA complaintsNext: VERTANICAL’s VER-01 gains FDA breakthrough status for low back pain Related Stories M&A / Deals Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar pharminent July 10, 2026 M&A / Deals GSK ends dementia alliance with Alector after setbacks pharminent July 9, 2026 M&A / Deals AstraZeneca, GSK intensify China ties with Sino Biopharm deals pharminent July 8, 2026
